Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mycophenolic Acid 2Busulfan 2Biopsy 2talimogene laherparepvec 1pembrolizumab 1fludarabine 1duvelisib 1Vincristine 1Transplantation 1Sirolimus 1Radiotherapy 1Prednisone 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Etoposide 1Cyclosporine 1Brentuximab Vedotin 1Blood Specimen Collection 1Aclarubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × Aclarubicin × 90 days × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡